– UK, Cambridge – Abcam plc (LON: ABC; | NASDAQ: ABCM), a global leader in the supply of life science research tools, today announced the appointments of Bessie Lee and Mark Capone to its Board as non-executive Directors, effective immediately.
Both Bessie and Mark bring extensive and complementary executive and non-executive experience to the Board of Abcam.
“I am delighted to welcome Bessie and Mark to the Board of Abcam. Bessie brings deep insight into customer and digital marketing dynamics in China, one of our key strategic markets, whilst Mark brings a wealth of experience within the life science sector and a first-hand understanding of our diagnostic and biopharma customers. Their expertise will be invaluable as we continue to work towards our long-term growth plans.” said Board Chairman, Peter Allen.
About Bessie Lee
Based in China, Bessie Lee is the CEO of Withinlink, a China-based venture capital firm and start-up incubator focused on marketing technology, which she founded in 2015. Before founding Withinlink, Bessie spent almost three decades at WPP plc, holding CEO roles in China for Mindshare, GroupM, and finally WPP.
Bessie is currently a non-executive Director of Electrocomponents plc, Homeplus Digital Co Ltd, and Shanghai Fuge Information Technology Co Ltd. She also acts as an Advisor to Didi Chuxing and Greater Pacific Capital.
About Mark Capone
Based in the US, Mark Capone is an accomplished life sciences executive with more than 35 years’ experience. He spent over 17 years with Myriad Genetics, latterly as CEO and President, over which time he grew the company into a leading global precision medicine company. Before joining Myriad Genetics, Mark spent 17 years with Eli Lilly and Company in positions across the entire value chain. Mark is currently the Chief Executive Officer of Precision Medicine Advisors, a consultancy for molecular diagnostics, pharmaceuticals, and biotechnology organizations, which he founded in 2020.
Mark Capone will join the Remuneration Committee.
About Abcam plc
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays, and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and eCommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam’s worldwide customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers, and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent program of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (LON: ABC) and its American Depositary Shares trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information: https://www.abcamplc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
